联芳基氨基噻嗪类BACE1抑制剂的3D—QSAR分析与分子对接研究(4)
參考文献
[ 1 ] QUERFURTH HW，LAFERLA FM. Alzheimer’s disease：mechanism of disease[J]. N Engl J Med，2010，362(4)：329-344.
[ 2 ] PRINCE M，GUERCHET M，PRINA M. The Global impact of dementia：2013-2050[R]. Health Services & Population Research，2013.
[ 3 ] LV ZY，TAN CC，YU JT，et al.Spreading of pathology in Alzheimer’s disease[J]. Neurotox Res，2017，32(4)：707- 722.
[ 4 ] MOORTHI V，PREETHI B. A review on Alzhimer’s disease：pathology，molecular conditions，managemnt and causes[J]. Asian J Pharm Clin Res，2017，10(5)：27.
, 百拇医药
[ 5 ] VASSAR R，KOVACS DM，YAN R，et al. The β-secretase enzyme BACE in health and Alzheimer’s disease：regulation，cell biology，function，and therapeutic potential[J]. J Neurosci，2009，29(41)：12787-12794.
[ 6 ] HUNT KW， COOK AW， WATTS RJ， et al. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1(BACE1)inhibitors：from hit to lowering of cerebrospinal fluid (CSF)amyloid β in a higher species[J]. J Med Chem，2013，56(8)：3379-3403.
, 百拇医药
[ 7 ] CHEN JJ，LIU Q，YUAN C，et al. Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease[J]. Bioorg Med Chem Lett，2015，25(4)：767-774.
[ 8 ] MANDAL M，ZHU Z，CUMMING JN，et al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1(BACE1)inhibitors：conformational constraint to favor a bioactive conformation[J]. J Med Chem，2012，55(21)：9331-9345.
, http://www.100md.com
[ 9 ] MAY PC，DEAN RA，LOWE SL，et al. Robust central reduction of amyloid-β in humans with an orally available，non-peptidic β-secretase inhibitor[J]. J Neurosci，2011，31(46)：16507-16516.
[10] WU YJ，JASON G，SHI JL，et al. Discovery of S3-truncated，C-6 heteroaryl substituted aminothiazine β-site APP cleaving enzyme-1(BACE1)inhibitors[J]. J Med Chem，2016，59(18)：8593-8600.
[11] LI HN，LI FR，CHENG MS，et al. Advances on non-peptide BACE1 inhibitors[J]. Chin J Med Chem，2016，26(6)：498-508.
, 百拇医药
[12] PUTZ MV，DUDA? NA. Variational principles for mechanistic quantitative structure-activity relationship (QSAR)studies：application on uracil derivatives’ anti-HIV action[J]. Struct Chem，2013，24(6)：1873-1893.
[13] SAMMI T，SILAKARI O，RAVIKUMAR M. Three-dimensional quantitative structure-activity relationship modeling of gamma-secretase inhibitors using molecular field analysis[J]. Chem Biol Drug Des，2008，71(2)：155-166.
[14] ENTEZARI HY，SERESHTI H，SABOURY AA，et al.3D QSAR studies，pharmacophore modeling，and virtual screening of diarylpyrazole-benzenesulfonamide derivatives as a template to obtain new inhibitors，using human carbonic anhydrase Ⅱ as a model protein[J]. J Enzym Inhib Med Chem，2017，32(1)：688-700., 百拇医药(刘景陶 倪敬轩 王晓 毕毅)
[ 1 ] QUERFURTH HW，LAFERLA FM. Alzheimer’s disease：mechanism of disease[J]. N Engl J Med，2010，362(4)：329-344.
[ 2 ] PRINCE M，GUERCHET M，PRINA M. The Global impact of dementia：2013-2050[R]. Health Services & Population Research，2013.
[ 3 ] LV ZY，TAN CC，YU JT，et al.Spreading of pathology in Alzheimer’s disease[J]. Neurotox Res，2017，32(4)：707- 722.
[ 4 ] MOORTHI V，PREETHI B. A review on Alzhimer’s disease：pathology，molecular conditions，managemnt and causes[J]. Asian J Pharm Clin Res，2017，10(5)：27.
, 百拇医药
[ 5 ] VASSAR R，KOVACS DM，YAN R，et al. The β-secretase enzyme BACE in health and Alzheimer’s disease：regulation，cell biology，function，and therapeutic potential[J]. J Neurosci，2009，29(41)：12787-12794.
[ 6 ] HUNT KW， COOK AW， WATTS RJ， et al. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1(BACE1)inhibitors：from hit to lowering of cerebrospinal fluid (CSF)amyloid β in a higher species[J]. J Med Chem，2013，56(8)：3379-3403.
, 百拇医药
[ 7 ] CHEN JJ，LIU Q，YUAN C，et al. Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease[J]. Bioorg Med Chem Lett，2015，25(4)：767-774.
[ 8 ] MANDAL M，ZHU Z，CUMMING JN，et al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1(BACE1)inhibitors：conformational constraint to favor a bioactive conformation[J]. J Med Chem，2012，55(21)：9331-9345.
, http://www.100md.com
[ 9 ] MAY PC，DEAN RA，LOWE SL，et al. Robust central reduction of amyloid-β in humans with an orally available，non-peptidic β-secretase inhibitor[J]. J Neurosci，2011，31(46)：16507-16516.
[10] WU YJ，JASON G，SHI JL，et al. Discovery of S3-truncated，C-6 heteroaryl substituted aminothiazine β-site APP cleaving enzyme-1(BACE1)inhibitors[J]. J Med Chem，2016，59(18)：8593-8600.
[11] LI HN，LI FR，CHENG MS，et al. Advances on non-peptide BACE1 inhibitors[J]. Chin J Med Chem，2016，26(6)：498-508.
, 百拇医药
[12] PUTZ MV，DUDA? NA. Variational principles for mechanistic quantitative structure-activity relationship (QSAR)studies：application on uracil derivatives’ anti-HIV action[J]. Struct Chem，2013，24(6)：1873-1893.
[13] SAMMI T，SILAKARI O，RAVIKUMAR M. Three-dimensional quantitative structure-activity relationship modeling of gamma-secretase inhibitors using molecular field analysis[J]. Chem Biol Drug Des，2008，71(2)：155-166.
[14] ENTEZARI HY，SERESHTI H，SABOURY AA，et al.3D QSAR studies，pharmacophore modeling，and virtual screening of diarylpyrazole-benzenesulfonamide derivatives as a template to obtain new inhibitors，using human carbonic anhydrase Ⅱ as a model protein[J]. J Enzym Inhib Med Chem，2017，32(1)：688-700., 百拇医药(刘景陶 倪敬轩 王晓 毕毅)